Why "test all tumor markers" is a bad idea
A tumor marker is a protein whose level can rise with cancer — the key word being "can." The same proteins rise with inflammation, benign disease, and physiological states, while some tumors produce no markers at all.
The outcome is predictable: a randomly raised number in a healthy person triggers weeks of anxiety and investigations that find nothing. That is why tumor markers appear in no international screening protocol for people without symptoms — apart from specific situations.
PSA: the one with caveats
PSA comes closest to a screening marker, but with caveats. It rises with benign enlargement and prostatitis, so a positive result is not a diagnosis but a reason for MRI and a urologist; only biopsy confirms cancer. The decision to test is shared with a doctor after 45–50, earlier with family history.
The usual landmark is up to 4.0 ng/mL (4.0 µg/L), and below 2.5 ng/mL (2.5 µg/L) for men under 50. But the trend matters more than any single value: a steady year-on-year climb worries more than one moderately raised number after a bike ride.
CA-125 and AFP: by indication, not "just in case"
CA-125 rises with endometriosis, inflammation, and during menstruation — as a screen for ovarian cancer in healthy women it is useless and harmful. Its real work is evaluating an already-detected mass together with ultrasound and monitoring treatment in patients with a confirmed diagnosis.
AFP rises with hepatitis and cirrhosis — and that is its place: in chronic liver disease it is tracked over time together with regular ultrasound, because a normal AFP does not exclude liver cancer. Its second field is germ cell tumors, where AFP and hCG are tested together as ordered by an oncologist.
What replaces the "anxiety panel"
Proven screening looks different: mammography, colonoscopy or stool blood testing after 45–50, HPV testing. These look for specific diseases where an early find genuinely changes the outcome.
From blood tests, simple lines contribute to cancer vigilance: a complete blood count (anemia, differential shifts) and nonspecific inflammation markers. Any persistent deviation is a reason not to panic but to methodically look for a cause with a doctor.
When a tumor marker is appropriate
- PSA — after a shared decision with a urologist, usually after 45–50
- CA-125 — with an ovarian mass already found, and in treatment monitoring
- AFP — in cirrhosis and chronic hepatitis, together with ultrasound
- hCG and AFP — in germ cell tumors as ordered by an oncologist
- Any marker — to follow an already confirmed disease
Markers covered in this article
Several markers on your report?
See how MedProtect explains results in the app: the whole report, a check of the recognized values, and a clear breakdown.
Frequently asked questions
A marker came back high — what first?
Do normal markers guarantee there is no tumor?
Why did my doctor order a tumor marker then?
Sources
- Prostate-specific antigen (PSA) blood test: MedlinePlus Medical Encyclopedia — MedlinePlus, National Library of Medicine. Accessed: August 31, 2026.
- CA-125 blood test: MedlinePlus Medical Encyclopedia — MedlinePlus, National Library of Medicine. Accessed: August 31, 2026.
- Alpha fetoprotein: MedlinePlus Medical Encyclopedia — MedlinePlus, National Library of Medicine. Accessed: August 31, 2026.